awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q36287386-1E578345-3758-49FE-AFDE-06994DA191A5
Q36287386-1E578345-3758-49FE-AFDE-06994DA191A5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36287386-1E578345-3758-49FE-AFDE-06994DA191A5
A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results.
P2860
Q36287386-1E578345-3758-49FE-AFDE-06994DA191A5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36287386-1E578345-3758-49FE-AFDE-06994DA191A5
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
787a360abd28e74104fe62844255ff22be08f86b
P2860
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries